An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Consultant psychiatrist Christopher Chan said: “This is high, relative to other options.” Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for ...

Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.